Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1 to 12. (canceled)

13. (currently amended) A method of treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent comprising administering to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound ~~according to Claim 1~~ of Formula I or Formula II



Formula I



Formula II

or a pharmaceutically acceptable salt thereof, wherein

each s is independently 1 or 2;
k is 1, 2, 3 or 4;
each m is independently 0, 1, 2, 3 or 4;
each X is independently O or S;
Y is a bond, S, O or NR_1, wherein R1 is hydrogen or C_{1-6}alkyl;
R is hydrogen or C_{1-6}alkyl;
the Linker is selected from the group consisting of:

(a) $-(CH_2)_n$, wherein n is 0, 1, 2, 3 or 4,

(b) C_{3-6}cycloalkyl, wherein the C_{3-6}cycloalkyl optionally mono-, di- or tri-substituted with a substituent selected from the group consisting of

(1) halo,
(2) C_{1-3}alkyl,
(3) C_{1-3}alkoxy,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,
(7) CF_3,
(8) CN;
(9) CH_2COOH
(10) $CH2COO\text{-}C_{1-3}$alkyl,
(11) C_{1-3}alkthio,

(c) aryl, wherein the aryl is selected from the group consisting of phenyl and naphthyl, wherein the aryl is optionally mono-, di- or tri-substituted with a substituent selected from the group consisting of

(1) halo,
(2) C_{1-3}alkyl,
(3) C_{1-3}alkoxy,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,
(7) CF_3,

(8) CN;
(9) CH_2COOH
(10) $CH2COO\text{-}C_{1\text{-}3}alkyl$,
(11) $C_{1\text{-}3}alkthio$,

(d) Heteroaryl optionally mono-, di- or tri- substituted with substituents selected from the group consisting of
(1) halo,
(2) $C_{1\text{-}3}alkyl$,
(3) $C_{1\text{-}3}alkoxy$,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,
(7) CF_3,
(8) CN;
(9) CH_2COOH
(10) $CH2COO\text{-}C_{1\text{-}3}alkyl$,
(11) $C_{1\text{-}3}alkthio$.

14. (original) The method according to Claim 13 wherein the patient is also at risk of a thrombotic cardiovascular event.

15. (currently amended) A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising administering to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound ~~according to Claim 1~~ of Formula I or Formula II



Formula I



Formula II

or a pharmaceutically acceptable salt thereof, wherein

each s is independently 1 or 2;
k is 1, 2, 3 or 4;
each m is independently 0, 1, 2, 3 or 4;
each X is independently O or S;
Y is a bond, S, O or NR_1, wherein R1 is hydrogen or C_{1-6}alkyl;
R is hydrogen or C_{1-6}alkyl;
the Linker is selected from the group consisting of:

(a) $-(CH_2)_n$, wherein n is 0, 1, 2, 3 or 4,

(b) C_{3-6}cycloalkyl, wherein the C_{3-6}cycloalkyl optionally mono-, di- or tri-substituted with a substituent selected from the group consisting of

(1) halo,
(2) C_{1-3}alkyl,
(3) C_{1-3}alkoxy,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,
(7) CF_3,
(8) CN;
(9) CH_2COOH
(10) CH2COO-C_{1-3}alkyl,
(11) C_{1-3}alkthio,

(c) aryl, wherein the aryl is selected from the group consisting of phenyl and naphthyl, wherein the aryl is optionally mono-, di- or tri-substituted with a substituent selected from the group consisting of

(1) halo,
(2) C_{1-3}alkyl,
(3) C_{1-3}alkoxy,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,
(7) CF_3,
(8) CN;
(9) CH_2COOH
(10) CH2COO-C_{1-3}alkyl,
(11) C_{1-3}alkthio,

(d) Heteroaryl optionally mono-, di- or tri- substituted with substituents selected from the group consisting of

(1) halo,
(2) C_{1-3}alkyl,
(3) C_{1-3}alkoxy,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,

(7) CF_3,

(8) CN;

(9) CH_2COOH

(10) $CH2COO\text{-}C_{1\text{-}3}alkyl$,

(11) $C_{1\text{-}3}alkthio$.

16. (canceled)

17. (currently amended) A method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a compound ~~according to Claim 1~~ of Formula I or Formula II



Formula I



Formula II

or a pharmaceutically acceptable salt thereof, wherein

each s is independently 1 or 2;
k is 1, 2, 3 or 4;
each m is independently 0, 1, 2, 3 or 4;
each X is independently O or S;
Y is a bond, S, O or NR_1, wherein R1 is hydrogen or C_{1-6}alkyl;
R is hydrogen or C_{1-6}alkyl;
the Linker is selected from the group consisting of:

(a) $-(CH_2)_n$, wherein n is 0, 1, 2, 3 or 4,

(b) C_{3-6}cycloalkyl, wherein the C_{3-6}cycloalkyl optionally mono-, di- or tri-substituted with a substituent selected from the group consisting of

(1) halo,
(2) C_{1-3}alkyl,
(3) C_{1-3}alkoxy,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,
(7) CF_3,
(8) CN;
(9) CH_2COOH
(10) $CH2COO-C_{1-3}$alkyl,
(11) C_{1-3}alkthio,

(c) aryl, wherein the aryl is selected from the group consisting of phenyl and naphthyl, wherein the aryl is optionally mono-, di- or tri-substituted with a substituent selected from the group consisting of

(1) halo,
(2) C_{1-3}alkyl,
(3) C_{1-3}alkoxy,
(4) Hydroxy,

(5) NO_2,
(6) CO_2,
(7) CF_3,
(8) CN;
(9) CH_2COOH
(10) $CH2COO\text{-}C_{1\text{-}3}alkyl$,
(11) $C_{1\text{-}3}alkthio$,

(d) Heteroaryl optionally mono-, di- or tri- substituted with substituents selected from the group consisting of
(1) halo,
(2) $C_{1\text{-}3}alkyl$,
(3) $C_{1\text{-}3}alkoxy$,
(4) Hydroxy,
(5) NO_2,
(6) CO_2,
(7) CF_3,
(8) CN;
(9) CH_2COOH
(10) $CH2COO\text{-}C_{1\text{-}3}alkyl$,
(11) $C_{1\text{-}3}alkthio$,

in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event.

18. to 26. (canceled)

27. (currently amended) ~~A compound~~ The method according to Claim 17 wherein the compound is selected from the following group:





















or a pharmaceutically acceptable salt of any of the foregoing compounds.

28. (canceled)